^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
ThyroidPrint©

Company:
GeneproDx
Type:
Laboratory Developed Test
Evidence

News

29d
Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review. (PubMed, Endocrine)
This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.
Journal • Review
|
Afirma® Genomic Sequencing Classifier • ThyGeNEXT® + ThyraMIR® • ThyroidPrint©
7ms
ThyroidPrint®: clinical utility for indeterminate thyroid cytology. (PubMed, Endocr Relat Cancer)
False-positive cases included four benign follicular nodules, six follicular and four oncotytic adenomas. Our results show that, physicians chose active surveillance instead diagnostic surgery in all patients with a benign ThyroidPrint® result, reducing the need for diagnostic surgery in 67% in patients with preoperative diagnosis of ITN.
Journal • Cytology
|
ThyroidPrint©
almost2years
Launch
|
ThyroidPrint©